Progressive Therapeutics Inc (PTI) is a technology company.
Progressive Therapeutics Inc (PTI) has raised $5.0M across 1 funding round.
Progressive Therapeutics Inc (PTI) has raised $5.0M in total across 1 funding round.
Progressive Therapeutics Inc (PTI) is a life sciences company focused on developing novel psychoactive and psychedelic therapeutics aimed at treating mental health disorders. Their work targets conditions such as ADHD, bipolar disorder, PTSD, and other psychiatric illnesses, positioning PTI at the forefront of innovative mental health solutions. PTI serves patients and healthcare providers by offering advanced psychiatric care, including medication management and telepsychiatry services, which enhance accessibility and personalized treatment. The company is experiencing growth momentum by integrating cutting-edge research and technology to improve mental wellness outcomes[1][2][3][4][7].
Founded in 2006, Progressive Therapeutics was co-founded by Dr. Maitri Patel, an adult psychiatrist with specialty training in child and adolescent psychiatry from Harvard hospitals. Dr. Patel’s expertise in diagnosing complex psychiatric conditions and her commitment to teaching psychopharmacology helped shape the company’s mission. The idea emerged from a desire to deliver high-quality, accessible psychiatric care using technology such as telemedicine to broaden patient access. Early traction came from establishing a strong clinical practice that combined medication management with flexible scheduling and telepsychiatry, setting a foundation for growth and innovation in mental health treatment[4].
Progressive Therapeutics rides the growing trend of integrating psychedelic and psychoactive compounds into mainstream mental health treatment, a field gaining momentum due to increasing recognition of mental health disorders and limitations of existing therapies. The timing is favorable given rising societal awareness, regulatory openness, and technological advances in telemedicine. Market forces such as the global mental health crisis and demand for innovative, accessible care solutions work in PTI’s favor. By combining novel therapeutics with telepsychiatry, PTI influences the broader ecosystem by expanding treatment modalities and improving care delivery models[2][3][4][7].
Looking ahead, Progressive Therapeutics is poised to expand its impact by advancing clinical development of novel therapeutics and scaling telepsychiatry services. Trends shaping their journey include increased acceptance of psychedelic therapies, digital health integration, and personalized medicine approaches. Their influence may evolve from a regional psychiatric care provider to a leader in next-generation mental health therapeutics and care delivery innovation. This trajectory aligns with their founding mission to empower individuals on their mental wellness journey through cutting-edge science and compassionate care[2][4][7].
Progressive Therapeutics Inc (PTI) has raised $5.0M in total across 1 funding round.
Progressive Therapeutics Inc (PTI)'s investors include KittyHawk Ventures, Telstra Ventures, Steve Wozniak.
Progressive Therapeutics Inc (PTI) has raised $5.0M across 1 funding round. Most recently, it raised $5.0M Seed in November 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 1, 2021 | $5.0M Seed | KittyHawk Ventures, Telstra Ventures, Steve Wozniak |